News

An immune regulatory molecule known as NEAT1 is produced at greater levels in the immune T-cells of people with primary Sjogren’s syndrome, and these levels seem to correlate with disease duration, a study has found. The findings suggest that NEAT1 may be used as a new…

Using the PI3K-delta inhibitor seletalisib as an add-on to standard treatment showed a trend toward easing disease activity and  dryness, and significantly lowered patient-reported fatigue in people with primary Sjögren’s syndrome (pSS), according to data from a Phase 2 trial. Findings from this proof-of-concept study (NCT02610543) —…